NAS:SGEN (USA)
Business Description
Seagen Inc
NAICS : 325414
SIC : 2836
21823 - 30th Drive South East, Building 3, Bothell, WA, USA, 98021
Compare
Compare
Traded in other countries / regions
S1GE34.Brazil
•
SGT.Germany
•
0A8R.UK
•
SGEN.USA
Description
Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 36.86 | |||||
| Equity-to-Asset | 0.81 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.08 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 27.73 | |||||
| Beneish M-Score | -2.58 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 27.7 | |||||
| 3-Year EBITDA Growth Rate | -30.7 | |||||
| 3-Year EPS without NRI Growth Rate | -37.9 | |||||
| 3-Year FCF Growth Rate | -28.5 | |||||
| 3-Year Book Growth Rate | 28.1 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 26.24 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 49.02 | |||||
| 9-Day RSI | 51.63 | |||||
| 14-Day RSI | 54.68 | |||||
| 6-1 Month Momentum % | 28.16 | |||||
| 12-1 Month Momentum % | 8.98 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.57 | |||||
| Quick Ratio | 4.04 | |||||
| Cash Ratio | 3.04 | |||||
| Days Inventory | 229.28 | |||||
| Days Sales Outstanding | 81.92 | |||||
| Days Payable | 109.24 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.6 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 79.58 | |||||
| Operating Margin % | -41.41 | |||||
| Net Margin % | -41.61 | |||||
| ROE % | -23.78 | |||||
| ROA % | -19.57 | |||||
| ROIC % | -65.04 | |||||
| ROC (Joel Greenblatt) % | -159.72 | |||||
| ROCE % | -22.93 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 18.13 | |||||
| PB Ratio | 11.05 | |||||
| Price-to-Tangible-Book | 13.45 | |||||
| EV-to-EBIT | -41.6 | |||||
| EV-to-Forward-EBIT | -47.44 | |||||
| EV-to-EBITDA | -46.79 | |||||
| EV-to-Forward-EBITDA | -54.77 | |||||
| EV-to-Revenue | 17.23 | |||||
| EV-to-Forward-Revenue | 17.01 | |||||
| EV-to-FCF | -46.98 | |||||
| Price-to-Projected-FCF | 96.6 | |||||
| Price-to-Median-PS-Value | 1.04 | |||||
| Price-to-Net-Current-Asset-Value | 15.57 | |||||
| Price-to-Net-Cash | 28.13 | |||||
| Earnings Yield (Greenblatt) % | -2.4 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:SGEN
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1,777.873 | ||
| EPS (TTM) ($) | -4.03 | ||
| Beta | 0.17 | ||
| Volatility % | 40.49 | ||
| 14-Day RSI | 54.68 | ||
| 14-Day ATR ($) | 5.136607 | ||
| 20-Day SMA ($) | 175.538 | ||
| 12-1 Month Momentum % | 8.98 | ||
| 52-Week Range ($) | 105.43 - 192.7867 | ||
| Shares Outstanding (Mil) | 184.44 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Seagen Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||